|
|
Dr. Laxmaiah Manchikanti brings some long overdue good news on ASIPP’s first live Annual Meeting since the COVID pandemic, moving to the pre-COVID era. He calls this déjà vu pre-COVID.
The 2021 Annual Meeting is designed with never-before-seen presentations for interventional pain physicians.
We hope you will join us June 24-26 in New Orleans, Louisiana!
|
|
India's hospitals and medical facilities across the country
are beyond capacity, having run out of oxygen and intensive
care beds. Hundreds of patients must await lifesaving care outside facilities in crowded city centers. Please join ASIPP Relief Fund
in bringing aid to the COVID outbreak in India by clicking here.
|
|
Healthcare providers can consider these strategies when developing a plan to transition to more frequent in-office treatment.
As the distribution of COVID-19 vaccines becomes increasingly effective, healthcare providers are preparing for a return to some sense of “normalcy,” including in-person patient visits. It’s easy to understand why: Most healthcare practices reported negative financial impacts due to the pandemic and attributed that to access to care.
While it’s tempting to advertise in-person procedures at the first available opportunity, many patients remain skeptical about safety. COVID-19 cases are trending upward worldwide with new mutations of the virus, so how do healthcare providers inspire patient confidence while also providing the safest treatment experience possible?
|
|
FDA officials argued authorization was necessary to help control the pandemic
Pfizer/BioNTech's COVID-19 vaccine was authorized for use in adolescents as young as 12, the first in the U.S. to receive emergency use authorization (EUA) in this younger age group, the FDA announced on Monday.
The agency amended the existing EUA to include teens ages 12 to 15 after the vaccine demonstrated 100% efficacy against symptomatic disease in this age group in a randomized trial. Pfizer's vaccine was first authorized in December 2020 for people 16 and older.
|
|
If you are registered to attend ASIPP's Annual Meeting, please send your questions in advance by clicking here.
Topics will include COVID-19, economics, burnout, social media, metabolic health, regulatory issues, scientific advances in IPM, and much more!
|
|
U.S. healthcare needs to stop preying on its people
After the coronavirus pandemic and our stalled national economy, it is America's runaway, intransigent, and immensely influential healthcare system that most urgently begs for the Biden administration's close attention. The excesses that characterize U.S. healthcare -- stratospheric unit pricing and wildly exorbitant overtreatment -- are deeply entrenched, and make it an increasingly unaffordable burden; one that threatens our national economic security and our global competitive standing, diverting precious resources from other vital needs like education, transportation, and infrastructure.
|
|
COVID-19's effect still to be determined
Just as reports of severe lung illnesses related to vaping began to make headlines in 2019, rates of cannabis vaping among high school students were soaring, according to high-quality survey data.
Results from the long-running Monitoring the Future study showed that 4.9% (95% CI 4.3%-5.5%) of high school students reported "frequent" vaping of cannabis products -- 10 or more times in the previous month -- up from 2.1% in 2018 (95% CI 1.7%-2.6%), reported Joseph J. Palamar, PhD, of New York University.
|
|
Regan Nichols, a former physician based in Midwest City, Okla., was convicted of second-degree murder after five of her patients died of opioid overdoses, according to a statement from Oklahoma Attorney General Mike Hunter.
The jury convicted Ms. Nichols on April 30.
Ms. Nichols was charged with murder in 2017 and later found guilty of knowingly prescribing controlled substances to patients without legitimate medical need, according to a statement from the attorney general's office. An investigation revealed Ms. Nichols prescribed the five patients more than 1,800 opioid pills in the month of their deaths.
|
|
If you have a question, please email Savannah Gold at sgold@asipp.org or call 270.554.9412, ext 4219.
|
- Selected manuscripts will be presented in an Electronic Poster Presentation
- Top 25 will be published in the Pain Physician journal.
- Top 10 will be selected for the Abstract Presentation at the Annual Meeting
|
|
A Sioux Falls, S.D.-based neurosurgeon and the two medical device distributorships he owns will pay $4.4 million to resolve False Claims Act violation allegations, the U.S. Justice Department said May 3.
Neither Wilson Asfora, MD, nor his Medical Designs and Sicage distributorships will be allowed to participate in federal healthcare programs for six years under terms of the settlement.
The federal government accused the companies of paying Dr. Asfora distributions in exchange for using their devices. The companies also allegedly resold other manufacturers devices and split profits with Dr. Asfora for devices he used. The companies separately paid $100,000 in penalties to settle allegations of violating the Open Payments program because Dr. Asfora's ownership and payments weren't reported to CMS.
|
|
Millions of transplant patients need to be informed that they may not get sufficient protection
I had a liver transplant in 2006. For the rest of my life, my body's immune system will consider my transplanted liver to be "foreign tissue" and will turn its weaponry against it as it would against an invading virus or bacteria. Of course, as opposed to a virus, I actually want to keep my new liver and so I must take immunosuppressants. I owe my life to these medications.
I've had a pretty challenging health history. Along with that transplant, I've dealt with a number of other diseases, surgeries, and hospitalizations. When COVID-19 came along, I didn't need to be told twice to be careful. Although I am only 57, it's unlikely I would fare well if I became infected with the virus. Social distancing and mask-wearing became the order of my days. My house, my wife, my two cats, curbside shopping, and Zoom have comprised most of my world for the past year.
|
|
Pain Medicine Case Reports (PMCR) and Editor-in-Chief Alaa Abd-Elsayed, MD, PhD would like to invite you to submit case reports and case series to the PMCR journal. Your article will be published free of charge.
Open access journals are freely available online for immediate worldwide open access to the full text of published articles. There is no subscription fee for open access journals. Open access journals are no different from traditional subscription-based journals: they undergo the same peer-review and quality control as any other scholarly journal.
Interested in becoming a member of the PMCR Editorial Board?
Editorial board members are asked to review 2-6 manuscripts per year. Please submit your most up-to-date CV to sgold@asipp.org for consideration.
For more information or to submit your articles, click here.
|
|
| CASE REPORT |
Rana Al-Jumah, MD, Jamal Hasson, MD, Ivan Urits, MD,
Amnon A. Berger, MD, PhD, Omar Viswanath, MD,
Alaa Abd-Elsayed, MD, and Musa Aner, MD
Abstract
BACKGROUND: Spinal cord stimulation (SCS) is a rapidly growing interventional treatment modality in chronic pain. Pain physicians are faced with the decision on how to manage patients on anticoagulation therapy given the risk of epidural hematomas.
CASE REPORT: We describe a patient with a history of atrial fibrillation and prior pulmonary embolism on chronic anticoagulation. The patient was planned to undergo an SCS trial, but was unable to discontinue all anticoagulation during the length of the trial. Utilizing a multidisciplinary approach, the patient discontinued warfarin 5 days prior to the procedure and began a therapeutic dose of low molecular weight heparin (LMWH). The final dose of LMWH was given 24 hours before the trial procedure. The patient then started prophylactic dosing of LMWH 24 hours after the trial procedure and continued that regimen for the course of the SCS trial. The last dose of prophylactic LMWH was given 24 hours before removal of the trial leads and the patient restarted 3 days of therapeutic LMWH along with resuming his normal anticoagulation regimen after lead removal. The patient was able to undergo a successful SCS trial and will be pursuing a SCS implant with further anticoagulation management.
|
|
| SYSTEMATIC REVIEW |
Jijun Xu, MD, PhD, Zhuo Sun, MD, Jiang Wu, MD,
Maunak Rana, MD, Joshua Garza, MD, Alyssa C. Zhu, MD,
Krishnan V. Chakravarthy, MD, PhD, Alaa Abd-Elsayed, MD,
Ellen Rosenquist, MD, Hersimren Basi, MD, Paul Christo, MD,
and Jianguo Cheng, MD, PhD
Abstract
BACKGROUND: Peripheral nerve stimulation (PNS) has been increasingly used to manage acute and chronic pain. However, the level of clinical evidence to support its use is not clear.
Objectives: To assess the clinical evidence of PNS in the treatment of acute or chronic pain.
|
|
| TECHNICAL GUIDE |
Guilherme Ferreira-Dos-Santos, MD, Mark-Friedrich B. Hurdle, MD, Sahil Gupta, MBBS, John Tran, HBSc, Anne M.R. Agur, PhD,
and Steven R Clendenen, MD.
Abstract
BACKGROUND: Over the last decade, several authors have reported that percutaneous peripheral nerve stimulation (PNS) can be used to assist in verifying the position of the procedure needle tip in relation to nerve structures, and that the combined technique using both ultrasound (US) guidance and PNS may serve as a reliable method for confirmation of the correct position of the procedure needle tip. It has also been reported that, when combined with US guidance, PNS may increase the success rate of pain management interventions.
OBJECTIVES: The aim of this technical report was to standardize an effective and easy to learn illustrated step-by-step technical approach to nerve identification during US-guided genicular nerve blocks, using percutaneous PNS as a verification instrument for procedure needle tip location.
|
|
Since this malpractice insurance program officially launched in November 2018, ASIPP has signed up hundreds of providers with an average savings of 30%. This is professional liability insurance tailored to our specialty and will stand up for us and defend our practices.
Norcal Mutual is 'A' Rated by AM best and is license in all 50 states. To read a few important points to keep in mind about the program, including discounts, administrative defense, cyber coverage, aggressive claims handling, and complimentary award-winning risk management CME activities, click here.
|
|
ASIPP® is now offering our members the benefit of a unique revenue cycle management/ billing service. We have received a tremendous amount of interest in the ASIPP® billing and coding program.
Click here to learn more about the negotiated rate for practices and more!
|
ASIPP® has formed a partnership with Henry Schein and PedsPal, a national GPO that has a successful history of negotiating better prices on medical supplies and creating value-added services for the independent physician. Working with MedAssets, PedsPal provides excellent pricing on products like contrast media that alleviate some of the financial pressures you experience today.
|
|
up-to-date news related to you, your practice, and your patients!
|
|
|
|
|
|
|
